Immunomodulatory cytokines and clonal dynamics in low-risk myelodysplastic syndromes patients treated with luspatercept

Am J Hematol. 2023 Nov;98(11):E345-E348. doi: 10.1002/ajh.27072. Epub 2023 Sep 12.

Authors

Bruno Fattizzo^{1

2}, Alfredo Marchetti^{1

2}, Anna Zaninoni¹, Marta Lionetti¹, Marta Riva³, Lorenzo Rizzo³, Loredana Pettine¹, Nicole Galli^{1

2}, Federico Mazzon³, Elisa Fermo¹, Akihiro Maeda², Alessio Marella², Matteo Claudio Da Vià¹, Francesco Passamonti^{1

2}, Niccolò Bolli^{1

2}, Wilma Barcellini¹

Affiliations

¹ Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
² Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
³ Department of Hematology and Oncology, Niguarda Cancer Center, ASST Ospedale Niguarda, Milan, Italy.

PMID: 37698348
DOI: 10.1002/ajh.27072

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Activin Receptors, Type II
Cytokines*
Humans
Immunoglobulin Fc Fragments
Myelodysplastic Syndromes* / drug therapy

Substances

luspatercept
Cytokines
Immunoglobulin Fc Fragments
Activin Receptors, Type II